Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
55.05 USD | -1.98% | -9.26% | -12.06% |
Apr. 18 | Citigroup Adjusts CRISPR Therapeutics' Price Target to $89 From $88, Keeps Buy Rating | MT |
Apr. 17 | Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.06% | 4.67B | |
-1.42% | 41.52B | |
+42.15% | 39.9B | |
+1.97% | 38.83B | |
-14.19% | 26.05B | |
+1.82% | 23.78B | |
-24.55% | 18.26B | |
-4.07% | 11.65B | |
+21.36% | 11.53B | |
+8.20% | 11.2B |
- Stock Market
- Equities
- CRSP Stock
- News CRISPR Therapeutics AG
- Chardan Adjusts CRISPR Therapeutics' Price Target to $164 from $168, Keeps Buy Rating